Neoantigen × AI
Daily research signal
TRACKING / TRIAL TRACKER

NCT06435351 — H. Lee Moffitt Cancer Center and Research… cancer vaccine trial

Personalized Dendritic Cell Vaccine Pilot for High Risk TNBC After Neoadjuvant Therapy

TrackingPhase EARLY_PHASE1RecruitingRegistry updated 1 Apr 2026
Phase EARLY_PHASE1phaseRecruitingregistry status16enrollment2029-05primary completion

Registry IDNCT06435351
Lead sponsorH. Lee Moffitt Cancer Center and Research Institute
Collaborators
PhasePhase EARLY_PHASE1
StatusRecruiting
IndicationBreast Cancer, Triple Negative Breast Cancer
Enrollment16 participants (target)
Start date2024-06-12
Primary completion2029-05 (est.)
Last registry update1 Apr 2026

Every field above is mirrored from the study record on ClinicalTrials.gov (NCT06435351), which the sponsor maintains and which carries the full protocol summary, eligibility criteria, sites and contacts. No neoantigen vaccine is approved anywhere yet — every program here is investigational, and inclusion is not an endorsement. See the methodology for how the tracker is built.

Daily coverage of the modality, tumor type and players this study touches:

What phase is NCT06435351?

NCT06435351 (Personalized Dendritic Cell Vaccine Pilot for High Risk TNBC After Neoadjuvant Therapy) is registered on ClinicalTrials.gov as Phase EARLY_PHASE1, sponsored by H. Lee Moffitt Cancer Center and Research Institute.

Is NCT06435351 recruiting?

As of the 2026-04-01 registry update, NCT06435351 is listed as "Recruiting". Eligibility criteria, study sites and contacts are maintained by the sponsor on the ClinicalTrials.gov record.

Who is running NCT06435351?

The lead sponsor is H. Lee Moffitt Cancer Center and Research Institute.

What condition does NCT06435351 study?

The registered conditions are Breast Cancer, Triple Negative Breast Cancer. Primary completion is listed as 2029-05 (estimated).

Are results available for NCT06435351?

neoag.ai mirrors the registry's factual fields — sponsor, phase, status and dates — and does not publish trial results. Any posted results, publications, or outcome measures appear on the ClinicalTrials.gov record for NCT06435351.

Back to the full neoantigen vaccine trial tracker 107 studies, refreshed daily from ClinicalTrials.gov. Background: primer, glossary, and the companies landscape.